Hengeler Mueller advises Epigenomics on mixed cash and non-cash capital increase
25. October 2018
Epigenomics has fully placed the new shares from the capital increase resolved on October 7, 2018 of up to EUR 12,007,180 (corresponds to 50% of the existing share capital). Accordingly, as of October 24, 2018, the Company’s share capital has been increased from EUR 24,014,360 to EUR 36,021,540 by 12,007,180 newly registered shares against contribution in cash and partly in kind.
Hengeler Mueller advised Epigenomics comprehensively on the mixed cash and non-cash capital increase from authorised capital that was subject to a prospectus. The team included partners Kai-Steffen Scholz (Corporate, Berlin) und Dirk Busch (Capital Markets, Düsseldorf) (both lead), counsel Steffen Hörner (Tax, Frankfurt) and Matthias Berberich (IP/IT, Berlin) as well as associates Oda Goetzke, Sahar Said (both Capital Markets, Düsseldorf), Ansgar Jahnke (Corporate and Capital Markets) and Deniz Tschammler (Public Law) (both Berlin).